Related Experiment Video
Updated: Jul 30, 2026
08:34
Isolation of Atrial Myocytes from Adult Mice
Published on: July 25, 2019
Atrial natriuretic peptide in human essential hypertension
Mayo Clinic Proceedings
|September 1, 1987
Summary
Circulating atrial natriuretic peptide (ANP) levels are slightly decreased, not elevated, in patients with essential hypertension. Treatment with a calcium channel blocker significantly reduced ANP levels.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Essential hypertension is a complex condition with various contributing factors.
- Atrial natriuretic peptide (ANP) plays a role in regulating blood pressure and fluid balance.
- Previous research suggested ANP levels might be elevated in hypertensive patients.
Purpose of the Study:
- To investigate circulating atrial natriuretic peptide (ANP) levels in patients with untreated essential hypertension.
- To determine the effect of antihypertensive treatment on ANP levels.
Main Methods:
- Measured plasma ANP concentrations in 62 hypertensive patients and 30 normotensive controls.
- Analyzed the relationship between ANP levels and blood pressure, plasma renin activity, and renal function.
- Assessed changes in ANP levels after treatment with nitrendipine (calcium channel blocker) or ketanserin.
Main Results:
- Hypertensive patients exhibited slightly lower ANP levels compared to normotensive subjects (27.4 vs. 35.3 pg/ml, P < 0.02).
- No correlation was found between ANP levels and diastolic blood pressure, plasma renin activity, or renal function.
- Nitrendipine treatment significantly reduced ANP levels in hypertensive patients (28.6 to 18.7 pg/ml, P < 0.05).
- Ketanserin treatment did not significantly alter ANP levels.
Conclusions:
- Circulating ANP levels are not elevated but slightly decreased in uncomplicated essential hypertension.
- Calcium channel antagonist therapy can reduce plasma ANP levels in hypertensive individuals.
Related Concept Videos
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:17Hormonal Regulation of Blood Pressure
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...